Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 3-DIMENSIONAL PHARMACEUTICALS (DDDP) -- Ignore unavailable to you. Want to Upgrade?

To: Spekulatius who wrote (16)	6/18/2001 11:04:38 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 146

Thanks, Ralf! The DuPont collaboration is for libraries and lead optimization, and it expires in about 6 months. If the "target" is dropped by Dupont (BMY), there's no potential upside. But, I doubt that committed funding, what little is left, is in danger. This ongoing distribution/selling/shorting/whatever is disturbing. I have a feeling that we're setting up for a big block. edit: I see that DuPont also has a DirectedDiversity license, so..... yes, there's likely to be some downside? A little? Or maybe DuPont was a happy camper, and BMY will make it whole. In any event, I don't see too much of a dent.